Enhancing insights into pulmonary vascular disease through a precision medicine approach: A joint nhlbi-cardiovascular medical research and education fund workshop report

John H. Newman, Stuart Rich, Steven H. Abman, John H. Alexander, John Barnard, Gerald J. Beck, Raymond L. Benza, Todd M. Bull, Stephen Y. Chan, Hyung J. Chun, Declan Doogan, Jocelyn Dupuis, Serpil C. Erzurum, Robert P. Frantz, Mark Geraci, Hunter Gillies, Mark Gladwin, Michael P. Gray, Anna R. Hemnes, Roy S. HerbstAdrian F. Hernandez, Nicholas S. Hill, Evelyn M. Horn, Kendall Hunter, Zhi Cheng Jing, Roger Johns, Sanjay Kaul, Steven M. Kawut, Tim Lahm, Jane A. Leopold, Greg D. Lewis, Stephen C. Mathai, Vallerie V. McLaughlin, Evangelos D. Michelakis, Steven D. Nathan, William Nichols, Grier Page, Marlene Rabinovitch, Jonathan Rich, Franz Rischard, Sharon Rounds, Sanjiv J. Shah, Victor F. Tapson, Naomi Lowy, Norman Stockbridge, Gail Weinmann, Lei Xiao

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The Division of Lung Diseases of the NHLBI and the Cardiovascular Medical Education and Research Fund held a workshop to discuss how to leverage the anticipated scientific output from the recently launched "Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics" (PVDOMICS) program to develop newer approaches to pulmonary vascular disease. PVDOMICS is a collaborative, protocol-driven network to analyze all patient populations with pulmonary hypertension to define novel pulmonary vascular disease (PVD) phenotypes. Stakeholders, including basic, translational, and clinical investigators; clinicians; patient advocacy organizations; regulatory agencies; and pharmaceutical industry experts, joined to discuss the application of precision medicine to PVD clinical trials. Recommendations were generated for discussion of research priorities in line with NHLBI Strategic Vision Goals that include: (1) A national effort, involving all the stakeholders, should seek to coordinate biosamples and biodata from all funded programs to a web-based repository so that information can be shared and correlated with other research projects. Example programs sponsored by NHLBI include PVDOMICS, Pulmonary Hypertension Breakthrough Initiative, the National Biological Sample and Data Repository for PAH, and the National Precision Medicine Initiative. (2) A task force to develop a master clinical trials protocol for PVD to apply precision medicine principles to future clinical trials. Specific features include: (a) adoption of smaller clinical trials that incorporate biomarker-guided enrichment strategies, using adaptive and innovative statistical designs; and (b) development of newer endpoints that reflect well-defined and clinically meaningful changes. (3) Development of updated and systematic variables in imaging, hemodynamic, cellular, genomic, and metabolic tests that will help precisely identify individual and shared features of PVD and serve as the basis of novel phenotypes for therapeutic interventions.

Original languageEnglish (US)
Pages (from-to)1661-1670
Number of pages10
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume195
Issue number12
DOIs
StatePublished - Jun 15 2017

Fingerprint

Precision Medicine
Financial Management
Medical Education
Vascular Diseases
Lung Diseases
Biomedical Research
Education
National Heart, Lung, and Blood Institute (U.S.)
Pulmonary Hypertension
Clinical Trials
Clinical Protocols
Phenotype
Patient Advocacy
Drug Industry
Advisory Committees
Research
Biomarkers
Hemodynamics
Research Personnel
Organizations

Keywords

  • Master protocol
  • Precision medicine
  • Pulmonary hypertension
  • Pulmonary vascular disease
  • Pulmonary vascular disease phenomics

ASJC Scopus subject areas

  • Medicine(all)
  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Enhancing insights into pulmonary vascular disease through a precision medicine approach : A joint nhlbi-cardiovascular medical research and education fund workshop report. / Newman, John H.; Rich, Stuart; Abman, Steven H.; Alexander, John H.; Barnard, John; Beck, Gerald J.; Benza, Raymond L.; Bull, Todd M.; Chan, Stephen Y.; Chun, Hyung J.; Doogan, Declan; Dupuis, Jocelyn; Erzurum, Serpil C.; Frantz, Robert P.; Geraci, Mark; Gillies, Hunter; Gladwin, Mark; Gray, Michael P.; Hemnes, Anna R.; Herbst, Roy S.; Hernandez, Adrian F.; Hill, Nicholas S.; Horn, Evelyn M.; Hunter, Kendall; Jing, Zhi Cheng; Johns, Roger; Kaul, Sanjay; Kawut, Steven M.; Lahm, Tim; Leopold, Jane A.; Lewis, Greg D.; Mathai, Stephen C.; McLaughlin, Vallerie V.; Michelakis, Evangelos D.; Nathan, Steven D.; Nichols, William; Page, Grier; Rabinovitch, Marlene; Rich, Jonathan; Rischard, Franz; Rounds, Sharon; Shah, Sanjiv J.; Tapson, Victor F.; Lowy, Naomi; Stockbridge, Norman; Weinmann, Gail; Xiao, Lei.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 195, No. 12, 15.06.2017, p. 1661-1670.

Research output: Contribution to journalArticle

Newman, JH, Rich, S, Abman, SH, Alexander, JH, Barnard, J, Beck, GJ, Benza, RL, Bull, TM, Chan, SY, Chun, HJ, Doogan, D, Dupuis, J, Erzurum, SC, Frantz, RP, Geraci, M, Gillies, H, Gladwin, M, Gray, MP, Hemnes, AR, Herbst, RS, Hernandez, AF, Hill, NS, Horn, EM, Hunter, K, Jing, ZC, Johns, R, Kaul, S, Kawut, SM, Lahm, T, Leopold, JA, Lewis, GD, Mathai, SC, McLaughlin, VV, Michelakis, ED, Nathan, SD, Nichols, W, Page, G, Rabinovitch, M, Rich, J, Rischard, F, Rounds, S, Shah, SJ, Tapson, VF, Lowy, N, Stockbridge, N, Weinmann, G & Xiao, L 2017, 'Enhancing insights into pulmonary vascular disease through a precision medicine approach: A joint nhlbi-cardiovascular medical research and education fund workshop report', American Journal of Respiratory and Critical Care Medicine, vol. 195, no. 12, pp. 1661-1670. https://doi.org/10.1164/rccm.201701-0150WS
Newman, John H. ; Rich, Stuart ; Abman, Steven H. ; Alexander, John H. ; Barnard, John ; Beck, Gerald J. ; Benza, Raymond L. ; Bull, Todd M. ; Chan, Stephen Y. ; Chun, Hyung J. ; Doogan, Declan ; Dupuis, Jocelyn ; Erzurum, Serpil C. ; Frantz, Robert P. ; Geraci, Mark ; Gillies, Hunter ; Gladwin, Mark ; Gray, Michael P. ; Hemnes, Anna R. ; Herbst, Roy S. ; Hernandez, Adrian F. ; Hill, Nicholas S. ; Horn, Evelyn M. ; Hunter, Kendall ; Jing, Zhi Cheng ; Johns, Roger ; Kaul, Sanjay ; Kawut, Steven M. ; Lahm, Tim ; Leopold, Jane A. ; Lewis, Greg D. ; Mathai, Stephen C. ; McLaughlin, Vallerie V. ; Michelakis, Evangelos D. ; Nathan, Steven D. ; Nichols, William ; Page, Grier ; Rabinovitch, Marlene ; Rich, Jonathan ; Rischard, Franz ; Rounds, Sharon ; Shah, Sanjiv J. ; Tapson, Victor F. ; Lowy, Naomi ; Stockbridge, Norman ; Weinmann, Gail ; Xiao, Lei. / Enhancing insights into pulmonary vascular disease through a precision medicine approach : A joint nhlbi-cardiovascular medical research and education fund workshop report. In: American Journal of Respiratory and Critical Care Medicine. 2017 ; Vol. 195, No. 12. pp. 1661-1670.
@article{aa83dcf383ef4eaaab894943e81982b6,
title = "Enhancing insights into pulmonary vascular disease through a precision medicine approach: A joint nhlbi-cardiovascular medical research and education fund workshop report",
abstract = "The Division of Lung Diseases of the NHLBI and the Cardiovascular Medical Education and Research Fund held a workshop to discuss how to leverage the anticipated scientific output from the recently launched {"}Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics{"} (PVDOMICS) program to develop newer approaches to pulmonary vascular disease. PVDOMICS is a collaborative, protocol-driven network to analyze all patient populations with pulmonary hypertension to define novel pulmonary vascular disease (PVD) phenotypes. Stakeholders, including basic, translational, and clinical investigators; clinicians; patient advocacy organizations; regulatory agencies; and pharmaceutical industry experts, joined to discuss the application of precision medicine to PVD clinical trials. Recommendations were generated for discussion of research priorities in line with NHLBI Strategic Vision Goals that include: (1) A national effort, involving all the stakeholders, should seek to coordinate biosamples and biodata from all funded programs to a web-based repository so that information can be shared and correlated with other research projects. Example programs sponsored by NHLBI include PVDOMICS, Pulmonary Hypertension Breakthrough Initiative, the National Biological Sample and Data Repository for PAH, and the National Precision Medicine Initiative. (2) A task force to develop a master clinical trials protocol for PVD to apply precision medicine principles to future clinical trials. Specific features include: (a) adoption of smaller clinical trials that incorporate biomarker-guided enrichment strategies, using adaptive and innovative statistical designs; and (b) development of newer endpoints that reflect well-defined and clinically meaningful changes. (3) Development of updated and systematic variables in imaging, hemodynamic, cellular, genomic, and metabolic tests that will help precisely identify individual and shared features of PVD and serve as the basis of novel phenotypes for therapeutic interventions.",
keywords = "Master protocol, Precision medicine, Pulmonary hypertension, Pulmonary vascular disease, Pulmonary vascular disease phenomics",
author = "Newman, {John H.} and Stuart Rich and Abman, {Steven H.} and Alexander, {John H.} and John Barnard and Beck, {Gerald J.} and Benza, {Raymond L.} and Bull, {Todd M.} and Chan, {Stephen Y.} and Chun, {Hyung J.} and Declan Doogan and Jocelyn Dupuis and Erzurum, {Serpil C.} and Frantz, {Robert P.} and Mark Geraci and Hunter Gillies and Mark Gladwin and Gray, {Michael P.} and Hemnes, {Anna R.} and Herbst, {Roy S.} and Hernandez, {Adrian F.} and Hill, {Nicholas S.} and Horn, {Evelyn M.} and Kendall Hunter and Jing, {Zhi Cheng} and Roger Johns and Sanjay Kaul and Kawut, {Steven M.} and Tim Lahm and Leopold, {Jane A.} and Lewis, {Greg D.} and Mathai, {Stephen C.} and McLaughlin, {Vallerie V.} and Michelakis, {Evangelos D.} and Nathan, {Steven D.} and William Nichols and Grier Page and Marlene Rabinovitch and Jonathan Rich and Franz Rischard and Sharon Rounds and Shah, {Sanjiv J.} and Tapson, {Victor F.} and Naomi Lowy and Norman Stockbridge and Gail Weinmann and Lei Xiao",
year = "2017",
month = "6",
day = "15",
doi = "10.1164/rccm.201701-0150WS",
language = "English (US)",
volume = "195",
pages = "1661--1670",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "12",

}

TY - JOUR

T1 - Enhancing insights into pulmonary vascular disease through a precision medicine approach

T2 - A joint nhlbi-cardiovascular medical research and education fund workshop report

AU - Newman, John H.

AU - Rich, Stuart

AU - Abman, Steven H.

AU - Alexander, John H.

AU - Barnard, John

AU - Beck, Gerald J.

AU - Benza, Raymond L.

AU - Bull, Todd M.

AU - Chan, Stephen Y.

AU - Chun, Hyung J.

AU - Doogan, Declan

AU - Dupuis, Jocelyn

AU - Erzurum, Serpil C.

AU - Frantz, Robert P.

AU - Geraci, Mark

AU - Gillies, Hunter

AU - Gladwin, Mark

AU - Gray, Michael P.

AU - Hemnes, Anna R.

AU - Herbst, Roy S.

AU - Hernandez, Adrian F.

AU - Hill, Nicholas S.

AU - Horn, Evelyn M.

AU - Hunter, Kendall

AU - Jing, Zhi Cheng

AU - Johns, Roger

AU - Kaul, Sanjay

AU - Kawut, Steven M.

AU - Lahm, Tim

AU - Leopold, Jane A.

AU - Lewis, Greg D.

AU - Mathai, Stephen C.

AU - McLaughlin, Vallerie V.

AU - Michelakis, Evangelos D.

AU - Nathan, Steven D.

AU - Nichols, William

AU - Page, Grier

AU - Rabinovitch, Marlene

AU - Rich, Jonathan

AU - Rischard, Franz

AU - Rounds, Sharon

AU - Shah, Sanjiv J.

AU - Tapson, Victor F.

AU - Lowy, Naomi

AU - Stockbridge, Norman

AU - Weinmann, Gail

AU - Xiao, Lei

PY - 2017/6/15

Y1 - 2017/6/15

N2 - The Division of Lung Diseases of the NHLBI and the Cardiovascular Medical Education and Research Fund held a workshop to discuss how to leverage the anticipated scientific output from the recently launched "Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics" (PVDOMICS) program to develop newer approaches to pulmonary vascular disease. PVDOMICS is a collaborative, protocol-driven network to analyze all patient populations with pulmonary hypertension to define novel pulmonary vascular disease (PVD) phenotypes. Stakeholders, including basic, translational, and clinical investigators; clinicians; patient advocacy organizations; regulatory agencies; and pharmaceutical industry experts, joined to discuss the application of precision medicine to PVD clinical trials. Recommendations were generated for discussion of research priorities in line with NHLBI Strategic Vision Goals that include: (1) A national effort, involving all the stakeholders, should seek to coordinate biosamples and biodata from all funded programs to a web-based repository so that information can be shared and correlated with other research projects. Example programs sponsored by NHLBI include PVDOMICS, Pulmonary Hypertension Breakthrough Initiative, the National Biological Sample and Data Repository for PAH, and the National Precision Medicine Initiative. (2) A task force to develop a master clinical trials protocol for PVD to apply precision medicine principles to future clinical trials. Specific features include: (a) adoption of smaller clinical trials that incorporate biomarker-guided enrichment strategies, using adaptive and innovative statistical designs; and (b) development of newer endpoints that reflect well-defined and clinically meaningful changes. (3) Development of updated and systematic variables in imaging, hemodynamic, cellular, genomic, and metabolic tests that will help precisely identify individual and shared features of PVD and serve as the basis of novel phenotypes for therapeutic interventions.

AB - The Division of Lung Diseases of the NHLBI and the Cardiovascular Medical Education and Research Fund held a workshop to discuss how to leverage the anticipated scientific output from the recently launched "Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics" (PVDOMICS) program to develop newer approaches to pulmonary vascular disease. PVDOMICS is a collaborative, protocol-driven network to analyze all patient populations with pulmonary hypertension to define novel pulmonary vascular disease (PVD) phenotypes. Stakeholders, including basic, translational, and clinical investigators; clinicians; patient advocacy organizations; regulatory agencies; and pharmaceutical industry experts, joined to discuss the application of precision medicine to PVD clinical trials. Recommendations were generated for discussion of research priorities in line with NHLBI Strategic Vision Goals that include: (1) A national effort, involving all the stakeholders, should seek to coordinate biosamples and biodata from all funded programs to a web-based repository so that information can be shared and correlated with other research projects. Example programs sponsored by NHLBI include PVDOMICS, Pulmonary Hypertension Breakthrough Initiative, the National Biological Sample and Data Repository for PAH, and the National Precision Medicine Initiative. (2) A task force to develop a master clinical trials protocol for PVD to apply precision medicine principles to future clinical trials. Specific features include: (a) adoption of smaller clinical trials that incorporate biomarker-guided enrichment strategies, using adaptive and innovative statistical designs; and (b) development of newer endpoints that reflect well-defined and clinically meaningful changes. (3) Development of updated and systematic variables in imaging, hemodynamic, cellular, genomic, and metabolic tests that will help precisely identify individual and shared features of PVD and serve as the basis of novel phenotypes for therapeutic interventions.

KW - Master protocol

KW - Precision medicine

KW - Pulmonary hypertension

KW - Pulmonary vascular disease

KW - Pulmonary vascular disease phenomics

UR - http://www.scopus.com/inward/record.url?scp=85021052328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021052328&partnerID=8YFLogxK

U2 - 10.1164/rccm.201701-0150WS

DO - 10.1164/rccm.201701-0150WS

M3 - Article

C2 - 28430547

AN - SCOPUS:85021052328

VL - 195

SP - 1661

EP - 1670

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 12

ER -